Across TCGA pan-cancer cohorts, ARMC1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ARMC1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ARMC1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARMC1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
BRCA and SKCM are the cancer types where ARMC1 Mutation most reproducibly stratifies survival.